Acrivon Therapeutics shareholders approve amended 2022 equity incentive plan
Acrivon Therapeutics, Inc. ACRV | 0.00 |
- Acrivon Therapeutics held its annual shareholder meeting on June 17, 2026.
- Shareholders adopted an amended and restated 2022 Equity Incentive Plan, lifting the share pool to 8,606,723 shares.
- The plan also provides for automatic annual share reserve increases through 2032 equal to 5% of fully diluted shares, unless the board sets less.
- Shareholders ratified PricewaterhouseCoopers as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
- Two directors were chosen to serve as Class I directors through the 2029 annual meeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-274410), on June 17, 2026, and is solely responsible for the information contained therein.
